Alaska biologics regulations.

Who may administer PRP, exosomes and stem cells in Alaska, and which agencies to check.

A physician at a desk reading regulatory documents

Who may administer biologics in Alaska?

Only licensed medical professionals, such as physicians or advanced practice providers (MD/DO) or under direct physician supervision, are permitted to perform stem cell therapies in Alaska.

Official sources

Alaska compliance guide.

FDA Compliance

The FDA regulates human cells, tissues, and cellular and tissue-based products (HCT/Ps) under the 21 CFR Part 1271. Clinics must determine if their products meet the criteria for minimal manipulation and homologous use to avoid extensive premarket approval processes. Key compliance points include:

  • Ensuring products meet the criteria for minimal manipulation.
  • Establishing that the intended use aligns with homologous use requirements.
  • Registering with the FDA if applicable and adhering to current Good Tissue Practice (cGTP) standards.

State Regulations

In addition to federal requirements, clinics must comply with Alaska state regulations. The Alaska Department of Health may have additional licensing requirements for biologics, depending on the scope of services offered. Understanding these state guidelines is key to accessible compliance and helps ensure that your clinic meets all necessary legal standards.

Provider Qualifications

Only licensed medical professionals, such as physicians or advanced practice providers (MD/DO) or under direct physician supervision, are permitted to perform stem cell therapies in Alaska. Ensure that your credentials align with state requirements to avoid legal issues. In many cases, meeting these qualifications is straightforward, encouraging new providers to consider expanding their services to include biologics.

Patient Informed Consent

Obtaining informed consent is a legal requirement and a critical component of patient care. The consent form should include:

  • A detailed explanation of the procedure, including potential risks and benefits.
  • A statement clarifying the experimental nature of certain therapies.
  • Disclosure of alternative treatment options.
  • Clear information on potential outcomes and limitations.

Pre-Treatment and Post-Treatment Protocols

Standard Operating Procedures (SOPs) for pre-treatment and post-treatment care help ensure patient safety and improve treatment outcomes. Consider implementing protocols that include:

  • Pre-treatment patient assessment and eligibility screening.
  • Clear guidelines for monitoring and follow-up care post-procedure.
  • Documentation practices to track patient progress and any adverse events.

Insurance Requirements

While many insurance plans do not currently cover stem cell therapies, maintaining appropriate malpractice and liability insurance is essential. This coverage helps protect your clinic against potential legal issues and reassures patients of your commitment to safety and compliance.

Compliant Marketing Practices

Marketing biologics and stem cell therapies requires careful attention to compliance to avoid misleading claims. Follow these best practices:

  • Ensure that marketing materials accurately represent the therapies' experimental status.
  • Avoid making claims about guaranteed outcomes or unproven benefits.
  • Use patient testimonials responsibly, with proper disclaimers about individual results.

This guide is a general summary to help clinics understand compliance requirements for biologics in Alaska. It is not legal advice. Regulations change; consult legal counsel and the agencies above before acting on it.

Alaska: common questions.

Who can administer stem cells, PRP and exosomes in Alaska?
Only licensed medical professionals, such as physicians or advanced practice providers (MD/DO) or under direct physician supervision, are permitted to perform stem cell therapies in Alaska. This is a general summary, not legal advice. Confirm with the state board.
Are stem cell and exosome therapies FDA-approved in Alaska?
FDA rules are federal, so they apply in Alaska as everywhere else. Exosome and stem cell therapies are not FDA-approved for therapeutic use, and PRP applications are considered off-label.
Do I need an IRB-approved study to offer biologics in Alaska?
Investigational treatment belongs inside a reviewed study with proper informed consent. IRB review is not FDA authorisation: culture-expanded and other more-than-minimally-manipulated cell products generally need an IND before use in people.
How do I start offering biologics in Alaska?
Start with the live webinar, then a discovery call and live training. After that we verify your Alaska licence, protocol, product sourcing, consent process and advertising before you are listed for patient inquiries.

Practising in Alaska? Start with the webinar.

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.